MYH9 and neoplasm: A case report on LUAD identified a novel MYH9-RETA fusion and T790M deletion in plasma circulating tumor DNA (ctDNA) following Osimotinib treatment, leading to rapid progression after 5 months and suggesting a potential resistance mechanism (Sun et al., 2020).